Isolated limb perfusion with TNFα and melphalan in a rat osteosarcoma model: A new anti-tumour approach

European Journal of Surgical Oncology

Volumn 22, Issue 2, 1996, Pages 152-157

  Manusama, Eric R ^a   Stavast, Jeroen ^a   Durante, Nicola M C ^a   Marquet, Richard L ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Oncology; Osteosarcoma; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HINDLIMB; LIMB PERFUSION; LIMB SALVAGE; MALE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RAT; REMISSION;

EID: 0029963270     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)90671-X     Document Type: Article

References (33)

1. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-6.
2. Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopaedics 1985; 8: 659-64.
3. Rosen GL, Marcove RC, Capparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-77.
4. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma. Results of randomized cooperative trial (Coss-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329-36.
5. Liénard D, Delmotte JJ, Renard N, Ewalenko P, Lejeune FJ. High doses of rTNF-α in combination with IFN-γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
6. Eggermont AMM, Liénard D, Schraffordt Koops H, Rosenkaimer F, Lejeune FJ. Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNFα in combination with gamma-Interferon and melphalan. In Fiers W. Buurman WA (eds) Tumor Necrosis Factor: Molecular and cellular biology and clinical relevance. Basel: Karger Verlag. 1993: 239-43.
7. Eggermont AMM, Schraffordt Koops H, Liénard D, Kroon BBR, Van Geel AN, Hoekstra HJ, Lejeune FJ. Isolated limb perfusion with high dose tumor necrosis factorα in combination with interferon-γ and melphalan for irresectable extremity soft tissue sarcomas: a multicenter trial. 1995, submitted.
8. Vaglini M, Cascinelli N, Picci P, Santinami M, Campanacci M. Combined treatment of osteosarcoma of the limbs at an advanced stage, including hyperthermic-antiblastic perfusion. Ital J Orth & Traum 1990; 16: 289-98.
9. Manusama ER, Nooijen PTGA, Durante NMC. Marquet RK, Eggermont AMM. Synergistic anti-tumour effect of recombinant human tumour necrosis factor α (TNFα) and melphalan in isolated limb perfusion in the rat. Br J Surg 1996.
10. Barendsen GW, Janse HC. Differences in effectiveness of combined treatments with ionizing radiation and vinblastine, evaluated for experimental sarcomas and squamous cell carcinomas in rats. Int J Radiat Oncol Biol Phys 1978; 4: 95-102.
11. Kramer SM. Carver ME. Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods 1986; 93: 201-6.
12. Benckhuijsen C, Van Dijk WJ, Van 't Hoff SC. High flow isolation perfusion of the rat hind limb in vivo. J Surg Oncol 1982; 21: 249-57.
13. Manusama ER, Durante NMC, Marquet RL, Eggermont AMM. Ischemia promotes the antitumor effect of tumor necrosis factor alpha (TNFα) in isolated limb perfusion in the rat. Reg Cancer Treat 1994; 7: 155-9.
14. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
15. Scannell G, Waxman K, Kami GJ. Ioli G, Gatanaga T, Yamamoto R, Granger GA. Hypoxia induces a human macrophage cell line to release tumor necrosis factor-alpha and its soluble receptors in vitro. J Surg Res 1993; 54: 281-5.
16. Van de Wiel PA, Bouman GJ, Van der Pijl A, Weitenberg ES, Lam BW, Bloksma N. Effect of tumor necrosis factor and lipid A on functional and structural vascular volume in solid murine tumors. Br J Cancer 1990; 62: 718-23.
17. Palladino MA Jr, Shalaby MR, Kramer SM, et al. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 1987; 138: 4023-32.
18. Manda T, Shimomura K, Mukumoto S, et al. Recombinant tumor necrosis factor-α: evidence of an indirect mode of activity. Cancer Res 1987; 47: 3707-11.
19. Carswell EA, Old LJ, Kassel RL, et al. An endotoxic induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-70.
20. Watanabe N, Niitsu Y, Umeno H, at al. Toxic effect of TNF on tumor vasculature in mice. Cancer Res 1988; 49: 2179-83.
21. Bloksma N, van de Wiel PA, Kuper CF, Hofhuis FMA. Multiple facets of induction of tumor necrosis. Ann Inst Pasteur/ Immunol 1988; 139: 294-9.
22. Nawroth P, Handley D, Matsueda G, et al. TNF/Cachectin-induced intravascular fibrin formation in Meth-A fibrosarcomas. J Exp Med 1988; 168: 637-47.
23. Sohmura Y, Nakata K, Yoshida H, Kashimoto S, Matsui Y, Furcuihi H. Recombinant human tumor necrosis factor-II. Antitumor effect on murine and human tumors transplanted in mice. J Immunopharmacol 1986; 8: 357-68.
24. Creasey AA, Reynolds T, Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 1986; 46: 5687-90.
25. Eggermont AMM. Schraffordt Koops H, Liénard D, Lejeune FJ, Ouderk M. Destruction of tumor associated vessels by isolated limb perfusion with TNFα: angiographic observations in sarcoma patients. Eur J Surg Oncol 1994; 20: 403.
26. Renard N, Nooijen P, Schalkwijk L, et al. Intravascular thrombocyte aggregation and erythrostasis are associated with necrosis in melanoma metastasis after perfusion with a high dose of tumor necrosis factor α (TNFα). J Pathol 1995; 176: 279-87.
27. Renard N. Liénard D, Lespagnard L, Eggermont AMM, Heimann R, Lejeune FJ. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (TNFα). Int J Cancer 1994; 57: 656-663.
28. Al Attiyah RA, Rosen H, Rook GAW. A model for the investigation of factors influencing hemorrhagic necrosis mediated by tumor necrosis factor in tissue sites primed with mycobacterial antigen preparations. Clin Exp Immunol 1992; 88: 537-42.
29. Yi ES, Ulich TR. Endotoxin, interleukin-1 and tumor necrosis factor cause meutrophil-dependent microvascular leakage in postcapillary venules. Am J Path 1992; 140: 659-62.
30. + cells. Cancer Immunol Immunother 1989; 28: 153-6.
31. Kachel DL, Martin WJ. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol & Exp Ther 1994; 268: 42-6.
32. Key ME, Brandhorst JS, Hanna MG. Synergistic effects of active therapy and specific chemotherapy in guinea pigs with disseminated cancer. J Immunol 1983; 130: 2987-92.
33. Folli S, Pelegrin A, Chaladon Y, Yao X, Buchegger F. Liénard D, Lejeune FJ, Mach JP. Tumor necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993; 53: 829-36.